高级检索
当前位置: 首页 > 详情页

AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [a]Department of Laboratory Medicine, The First Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China [b]Zhaotong Health School, Yunnan, China
出处:
ISSN:

关键词: Activation-induced cytidine deaminase Chronic myelocytic leukemia Imatinib Arsenic trioxide Mutation

摘要:
Activation-induced deaminase (AID), a cytidine deaminase, can accelerate the acquisition of BCR-ABL1 kinase domain mutations in human CML. In the present study, we investigated the expression of AID and Bcr-Abl in CML cells derived from 35 clinical patients. We found that both AID and Bcr-Abl were correlatively over-expressed in CML-LBC (lymphoid blast crisis) cells as compared with those in CMLCP (chronic phase) cells. AID expression was significantly decreased in CML-LBC cells after treated with arsenic trioxide, especially together with imatinib. We also observed satisfied therapy effects of As2O3 and imatinib on patients with CML blast crisis. These data suggest that decreasing AID expression in CML-LBC by As2O3 may be a promising approach to CML treatment. (C) 2011 Elsevier Ltd. All rights reserved.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 3 区 医学
小类 | 4 区 血液学 4 区 肿瘤学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 血液学 4 区 肿瘤学
JCR分区:
出版当年[2011]版:
Q2 HEMATOLOGY Q2 ONCOLOGY
最新[2023]版:
Q3 HEMATOLOGY Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者机构: [a]Department of Laboratory Medicine, The First Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China
通讯作者:
通讯机构: [*1]Department of Laboratory Medicine, The First Affiliated Hospital of KunMing Medical College, Xichang Road 295#, Kunming 650032, Yunnan, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52537 今日访问量:0 总访问量:1562 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)